STXS (Stereotaxis Corp) Market Value to Book Value Ratio

Stereotaxis Corp (STXS) - corporate logo

Stereotaxis, Inc. is expanding its cardiology presence through partnerships with clinics and catheter developers by implementing high-precision robots. The company generates revenue from the sale of high-cost systems and subsequent supplies of consumables. A visual representation of quotes with the 7.52 metric is available below. The business relies on robust patent protection and high customer switching costs, which ensure a stable service flow.

Market Capitalization to Net Assets: Stereotaxis Corporation (STXS) for 07/04/2022 - 10/27/2026
Finished products of Stereotaxis Inc

Stereotaxis, Inc. (STXS) maintains a high level of authority in robotic cardiology, driving expectations for asset value growth, as reflected in the market cap to book value ratio. This coefficient compares the business's market value to its net assets, demonstrating the premium investors are willing to pay for future technological breakthroughs and confirming the company's resilient position during its expansion phase.

Direct competitors

Boston Scientific - Market Value to Book Value Ratio|EW (edwards.com) - Market Capitalization to Book Value|RMD: Market Value to Book Value Ratio|Market Capitalization to Book Value PODD|ZBH - Market Value to Book Value Ratio|Market Capitalization to Net Assets CooperSurgical (COO)|ALGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio globusmedical.com GMED|TMDX: Market Capitalization to Book Value Ratio|ATEC - Market Cap to Net Assets Ratio|Artivion Inc - Market Capitalization to Book Value Ratio|Enovis Inc. (ENOV) - Market Capitalization to Book Value|IART (Integra LifeSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ESTA|Market Value to Book Value Ratio Beta Bionics (BBNX)|Market Value to Book Value Ratio IRADIMED Corp (IRMD)|Market Capitalization to Book Value Ratio EMBC|TNDM - Market Capitalization to Book Value|Market Cap to Net Assets Ratio AxoGen, Inc.|SIBN - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio OFIX|Bioventus Inc (BVS) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio OrthoPediatrics Corp (KIDS)|Capitalization to Book Value Ratio Treace Corp (TMCI)|Strata Critical Medical Inc (SRTA) - Market Cap to Net Assets Ratio|Market Value to Book Value CARL (carlsmed.com)|RxSight - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio ClearPoint Neuro Inc. CLPT|STIM (NeuroStar) - Market Capitalization to Book Value Ratio|SGHT - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Orchestra BioMed|Anika Therapeutics, Inc. (ANIK) - Capitalization to Book Value Ratio|NSPR: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Jin Medical International Ltd|Market Capitalization to Book Value Ratio VANI (Vivani Medical, Inc.)|Market Cap to Net Assets Ratio xtantmedical.com (XTNT)|Market Capitalization to Book Value Ratio NMTC (NeuroOne Medical Technologies)|Modular Medical Inc - Market Capitalization to Book Value Ratio|MYO - Market Value to Book Value Ratio|Envoy Medical Inc. (COCH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Vivos Therapeutics, Inc VVOS|enVVeno Corp (NVNO) - Market Value to Book Value|Market Capitalization to Book Value Ratio SINT (Sintx Technologies Inc)|Market-to-Book Ratio TNON|LFWD: Market Value to Book Value Ratio|Market Value to Equity Ratio autonomix.com AMIX|Market Cap to Net Assets Ratio IVF (INVO Bioscience, Inc.)|Market Capitalization to Book Value Ratio Bone Biologics Inc BBLG|Market Capitalization to Book Value Ratio AXNX (Axonics, Inc.)|BIOL: Market Capitalization to Book Value|Market Value to Book Value Ratio dynatronics.com (DYNT)|FNA (Paragon 28) - Market Capitalization to Net Assets|Market Value to Book Value Ratio INVO